UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease

Alzheimer's & dementia, 2022-12, Vol.18 (12), p.2669-2686

2022

Volltextzugriff (PDF)

pH-Evoked Dural Afferent Signaling Is Mediated by ASIC3 and Is Sensitized by Mast Cell Mediators

Headache, 2013-09, Vol.53 (8), p.1250-1261

2013

Volltextzugriff (PDF)

Activation of TRPA1 on dural afferents: A potential mechanism of headache pain

Pain (Amsterdam), 2012-09, Vol.153 (9), p.1949-1958

2012

Volltextzugriff (PDF)

Biochemical and pharmacological assessment of MAP-kinase signaling along pain pathways in experimental rodent models: a potential tool for the discovery of novel antinociceptive therapeutics

Biochemical pharmacology, 2014-02, Vol.87 (3), p.390-398

2014

Volltextzugriff (PDF)

Medullary pain facilitating neurons mediate allodynia in headache-related pain

Annals of neurology, 2009-02, Vol.65 (2), p.184-193

2009

Volltextzugriff (PDF)

Activation of TRPV4 on dural afferents produces headache-related behavior in a preclinical rat model

Cephalalgia, 2011-12, Vol.31 (16), p.1595-1600

2011

Volltextzugriff (PDF)

Translational animal models for Alzheimer's disease: An Alzheimer's Association Business Consortium Think Tank

Alzheimer's & dementia : translational research & clinical interventions, 2020, Vol.6 (1), p.e12114-n/a

2020

Volltextzugriff (PDF)

Mechanistic and pharmacological assessment of murine IL-23 mediated psoriasiform dermatitis; implications for drug discovery

Journal of dermatological science, 2018-10, Vol.92 (1), p.45-53

2018

Volltextzugriff (PDF)

Supporting participants and study partners when trials end as planned

Alzheimer's & dementia, 2023-04, Vol.19 (4), p.1590-1591

2023

Volltextzugriff (PDF)

The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau

Alzheimer's & dementia, 2021-09, Vol.17 (9), p.1575-1582

2021

Volltextzugriff (PDF)

Dural afferents express acid-sensing ion channels: A role for decreased meningeal pH in migraine headache

Pain (Amsterdam), 2011-01, Vol.152 (1), p.106-113

2011

Volltextzugriff (PDF)

Persistence of Inflammatory Phenotype in Residual Psoriatic Plaques in Patients on Effective Biologic Therapy

Journal of investigative dermatology, 2020-05, Vol.140 (5), p.1015-1025.e4

2020

Volltextzugriff (PDF)

IL‐36 receptor antagonistic antibodies inhibit inflammatory responses in preclinical models of psoriasiform dermatitis

Experimental dermatology, 2019-02, Vol.28 (2), p.113-120

2019

Volltextzugriff (PDF)

Putting participants and study partners FIRST when clinical trials end early

Alzheimer's & dementia, 2022-12, Vol.18 (12), p.2736-2746

2022

Volltextzugriff (PDF)

Participant FIRST: Improving Communication With and Support For Participants in Trials that End Early

Alzheimer's & dementia, 2022-12, Vol.18 (S10), p.n/a

2022

Volltextzugriff (PDF)

An experimental model of headache-related pain

Methods in molecular biology (Clifton, N.J.), 2012, Vol.851, p.109

2012

Volltextzugriff (PDF)

The Alzheimer's Association Appropriate Use Recommendations for Blood Biomarkers in Alzheimer’s Disease

Alzheimer's & dementia, 2022-12, Vol.18 (S6), p.n/a

2022

Volltextzugriff (PDF)

Plasma phosphorylated tau 217 levels are highly stable under common pre‐analytical sample handling procedures

Alzheimer's & dementia, 2023-12, Vol.19 (S14), p.n/a

2023

Volltextzugriff (PDF)

Towards clinical implementation: Establishing standardized operating procedures to limit the pre‐analytical sample handling effects on the novel Alzheimer’s disease blood‐based biomarkers

Alzheimer's & dementia, 2023-06, Vol.19 (S2), p.n/a

2023

Volltextzugriff (PDF)

A biorepository for the in‐depth validation of pre‐analytical sample handling effects on novel blood‐based biomarkers for Alzheimer’s disease: The first results

Alzheimer's & dementia, 2020-12, Vol.16, p.n/a

2020

Volltextzugriff (PDF)

A biorepository for the in‐depth validation of pre‐analytical sample handling effects on novel blood‐based biomarkers for Alzheimer’s disease: The first results: Biomarkers (non‐neuroimaging): Method development and validation

Alzheimer's & dementia, 2020-12, Vol.16 (S5)

2020

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(26)

Publikationsform

Sprache

Englisch
(30)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease

pH-Evoked Dural Afferent Signaling Is Mediated by ASIC3 and Is Sensitized by Mast Cell Mediators

Activation of TRPA1 on dural afferents: A potential mechanism of headache pain

Biochemical and pharmacological assessment of MAP-kinase signaling along pain pathways in experimental rodent models: a potential tool for the discovery of novel antinociceptive therapeutics

Medullary pain facilitating neurons mediate allodynia in headache-related pain

Activation of TRPV4 on dural afferents produces headache-related behavior in a preclinical rat model

Translational animal models for Alzheimer's disease: An Alzheimer's Association Business Consortium Think Tank

Mechanistic and pharmacological assessment of murine IL-23 mediated psoriasiform dermatitis; implications for drug discovery

Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group

Supporting participants and study partners when trials end as planned

The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau

Dural afferents express acid-sensing ion channels: A role for decreased meningeal pH in migraine headache

Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivity

Persistence of Inflammatory Phenotype in Residual Psoriatic Plaques in Patients on Effective Biologic Therapy

IL‐36 receptor antagonistic antibodies inhibit inflammatory responses in preclinical models of psoriasiform dermatitis

Putting participants and study partners FIRST when clinical trials end early

EEG measures for clinical research in major vascular cognitive impairment: recommendations by an expert panel

Participant FIRST: Improving Communication With and Support For Participants in Trials that End Early

Comparative analytical performance of multiple plasma A beta 42 and A beta 40 assays and their ability to predict positron emission tomography amyloid positivity

An experimental model of headache-related pain

The Alzheimer's Association Appropriate Use Recommendations for Blood Biomarkers in Alzheimer’s Disease

Plasma phosphorylated tau 217 levels are highly stable under common pre‐analytical sample handling procedures

Towards clinical implementation: Establishing standardized operating procedures to limit the pre‐analytical sample handling effects on the novel Alzheimer’s disease blood‐based biomarkers

A biorepository for the in‐depth validation of pre‐analytical sample handling effects on novel blood‐based biomarkers for Alzheimer’s disease: The first results

A biorepository for the in‐depth validation of pre‐analytical sample handling effects on novel blood‐based biomarkers for Alzheimer’s disease: The first results: Biomarkers (non‐neuroimaging): Method development and validation

Suchergebnisse filtern